Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

<p>Supplementary Figure 5</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Francisco Exposito (16721403) (author)
Autres auteurs:	Miriam Redrado (16721406) (author), Maeva Houry (16721409) (author), Katherine Hastings (16721412) (author), Magdalena Molero-Abraham (16721415) (author), Teresa Lozano (16721418) (author), Jose Luis Solorzano (16721421) (author), Julian Sanz-Ortega (16721424) (author), Vera Adradas (16721427) (author), Ramon Amat (16721430) (author), Esther Redin (16721433) (author), Sergio Leon (16721436) (author), Naroa Legarra (16721439) (author), Javier Garcia (16721442) (author), Diego Serrano (16721445) (author), Karmele Valencia (14962695) (author), Camila Robles-Oteiza (16721448) (author), Giorgia Foggetti (15118568) (author), Nerea Otegui (16721451) (author), Enriqueta Felip (16721454) (author), Juan J. Lasarte (16721457) (author), Luis Paz-Ares (16721460) (author), Jon Zugazagoitia (16721463) (author), Katerina Politi (15313362) (author), Luis Montuenga (16721466) (author), Alfonso Calvo (16721469) (author)
Publié:	2025
Sujets:	Cancer Cancer Biology Immuno-oncology Immunotherapy Combination immunotherapy Lung Cancer Oncogenes & Tumor Suppressors PD-1
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
par: Francisco Exposito (16721403)
Publié: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
par: Francisco Exposito (16721403)
Publié: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
par: Francisco Exposito (16721403)
Publié: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
par: Francisco Exposito (16721403)
Publié: (2025)

Processed single-cell RNA-seq dataset of cancer-associated fibroblasts in breast cancer patients receiving anti–PD-1 therapy
par: Thang Pham (19938126)
Publié: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
par: Caroline Robert (15032672)
Publié: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
par: Caroline Robert (15032672)
Publié: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
par: Caroline Robert (15032672)
Publié: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
par: Caroline Robert (15032672)
Publié: (2025)

Data Sheet 3_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
par: Hailong Pang (12841991)
Publié: (2025)

Data Sheet 2_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
par: Hailong Pang (12841991)
Publié: (2025)

Data Sheet 1_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
par: Hailong Pang (12841991)
Publié: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
par: Stéphane Fattori (15048281)
Publié: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
par: Stéphane Fattori (15048281)
Publié: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
par: Stéphane Fattori (15048281)
Publié: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
par: Stéphane Fattori (15048281)
Publié: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
par: Stéphane Fattori (15048281)
Publié: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
par: Stéphane Fattori (15048281)
Publié: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
par: Stéphane Fattori (15048281)
Publié: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
par: Stéphane Fattori (15048281)
Publié: (2025)

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
par: Stéphane Fattori (15048281)
Publié: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
par: Hiroshi Kagamu (14961732)
Publié: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
par: Ulka N. Vaishampayan (15051039)
Publié: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
par: Ulka N. Vaishampayan (15051039)
Publié: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
par: Ulka N. Vaishampayan (15051039)
Publié: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
par: Ulka N. Vaishampayan (15051039)
Publié: (2025)

Supplementary File 1 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
par: Huaibin Ge (15047462)
Publié: (2025)

Datasets for bibliometric analysis of regulatory T cells in gastric cancer (2005-2025)
par: Houshu Tu (22026668)
Publié: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
par: Lavanya Sivapalan (15314248)
Publié: (2025)

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
par: Rohit Thummalapalli (17314483)
Publié: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
par: Rohit Thummalapalli (17314483)
Publié: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
par: Rohit Thummalapalli (17314483)
Publié: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
par: Rohit Thummalapalli (17314483)
Publié: (2025)

Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
par: Rohit Thummalapalli (17314483)
Publié: (2025)

Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
par: Rohit Thummalapalli (17314483)
Publié: (2025)

Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
par: Rohit Thummalapalli (17314483)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_6e6nuj4el1969mmb76tfeajfts